Sydney-based biotech innovator All G has announced two major milestones, securing a USD$5.8 million capital injection and forging a joint venture with French dairy giant Armor Protéines. This dual achievement will accelerate the company's mission to commercialize its cow-free lactoferrin, produced via precision fermentation. The developments position All G to impact global markets for infant nutrition and therapeutic ingredients.
Securing Strategic Capital
The company raised $5.8 million through a convertible note, signaling strong investor confidence ahead of a planned Series B round. The funding was supported by existing investor Agronomics, a UK-listed firm, alongside Doehler Ventures and Singapore's ID Capital. This capital is instrumental in scaling production and preparing for a major market launch in the coming years.
Building on Strong Foundations
This latest injection builds upon a substantial funding history, with the company having previously raised approximately $23.3 million from diverse backers. Notable past investors include Woolworths' venture arm W23, the Clean Energy Innovation Fund, and Commonwealth Bank CEO Matt Comyn. This consistent financial support underscores the perceived value of All G's innovative biotechnology platform.
A Landmark Partnership with Armor Protéines
In a pivotal move, All G has entered a joint venture with Armor Protéines, a subsidiary of multinational Savencia Fromage & Dairy. The partnership combines All G's cutting-edge intellectual property with Armor Protéines' established manufacturing and commercialization infrastructure. This collaboration creates a powerful synergy for bringing novel dairy proteins to a global audience at scale.
Accelerating Global Market Access
The joint venture will focus on producing and commercializing both bovine and human lactoferrin for key international markets. All G will leverage Armor Protéines' extensive distribution networks across the United States, Asia, and Europe to expedite its entry. This alliance provides a clear and robust pathway to market, bypassing many logistical hurdles new biotech firms often face.
Pioneering Precision Fermentation
At the core of All G's innovation is its precision fermentation technology, which creates bio-identical dairy proteins without animals. The process utilizes bioreactors where microbes, programmed with milk DNA, efficiently produce complex proteins like lactoferrin. These pure ingredients are targeted for high-value applications including infant formula, personal care, and various therapeutics.
A Clear Path to Commercialization
The company has a clear product rollout strategy, with its bovine lactoferrin powder scheduled for release later this year. This will be followed by the launch of a synthetic human lactoferrin in early 2026, a key step in replicating components of human breast milk. This phased approach allows the company to establish its presence while developing next-generation products.
A Sharpened Corporate Focus
This new chapter for All G follows a strategic realignment, which saw the company spin off its plant-based meat brand, Love Buds, in late 2023. This decision allowed the startup to concentrate its resources exclusively on the high-margin precision fermentation business. The sharpened focus is aimed at capturing a leading position in the specialized market for alternative whey proteins.
Future Growth and Expansion
Looking ahead, All G is preparing to launch its Series B fundraising round within the next twelve months to fuel its next growth phase. The company is also pursuing further strategic partnerships, particularly with a Chinese pharmaceutical producer to capitalize on existing regulatory approval. These initiatives signal the company's ambitious plans for sustained expansion and market leadership.
The recent $5.8 million funding and strategic alliance with Armor Protéines mark a transformative moment for All G. These developments provide the capital and commercial infrastructure necessary to transition from a promising startup to a global commercial entity. By focusing on precision-fermented lactoferrin, All G is positioned to disrupt the traditional dairy supply chain and offer sustainable nutritional solutions worldwide.